243 related articles for article (PubMed ID: 15000491)
1. A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor.
Hirokawa Y; Tikoo A; Huynh J; Utermark T; Hanemann CO; Giovannini M; Xiao GH; Testa JR; Wood J; Maruta H
Cancer J; 2004; 10(1):20-6. PubMed ID: 15000491
[TBL] [Abstract][Full Text] [Related]
2. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1.
Kissil JL; Wilker EW; Johnson KC; Eckman MS; Yaffe MB; Jacks T
Mol Cell; 2003 Oct; 12(4):841-9. PubMed ID: 14580336
[TBL] [Abstract][Full Text] [Related]
3. Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2.
Yi C; Wilker EW; Yaffe MB; Stemmer-Rachamimov A; Kissil JL
Cancer Res; 2008 Oct; 68(19):7932-7. PubMed ID: 18829550
[TBL] [Abstract][Full Text] [Related]
4. Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts.
Tang Y; Chen Z; Ambrose D; Liu J; Gibbs JB; Chernoff J; Field J
Mol Cell Biol; 1997 Aug; 17(8):4454-64. PubMed ID: 9234703
[TBL] [Abstract][Full Text] [Related]
5. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.
Licciulli S; Maksimoska J; Zhou C; Troutman S; Kota S; Liu Q; Duron S; Campbell D; Chernoff J; Field J; Marmorstein R; Kissil JL
J Biol Chem; 2013 Oct; 288(40):29105-14. PubMed ID: 23960073
[TBL] [Abstract][Full Text] [Related]
6. CAPE (caffeic acid phenethyl ester)-based propolis extract (Bio 30) suppresses the growth of human neurofibromatosis (NF) tumor xenografts in mice.
Demestre M; Messerli SM; Celli N; Shahhossini M; Kluwe L; Mautner V; Maruta H
Phytother Res; 2009 Feb; 23(2):226-30. PubMed ID: 18726924
[TBL] [Abstract][Full Text] [Related]
7. PAK1 inhibition reduces tumor size and extends the lifespan of mice in a genetically engineered mouse model of Neurofibromatosis Type 2 (NF2).
Hawley E; Gehlhausen J; Karchugina S; Chow HY; Araiza-Olivera D; Radu M; Smith A; Burks C; Jiang L; Li X; Bessler W; Masters A; Edwards D; Burgin C; Jones D; Yates C; Clapp DW; Chernoff J; Park SJ
Hum Mol Genet; 2021 Aug; 30(17):1607-1617. PubMed ID: 34075397
[TBL] [Abstract][Full Text] [Related]
8. p21-activated kinase links Rac/Cdc42 signaling to merlin.
Xiao GH; Beeser A; Chernoff J; Testa JR
J Biol Chem; 2002 Jan; 277(2):883-6. PubMed ID: 11719502
[TBL] [Abstract][Full Text] [Related]
9. The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.
Zhou L; Lyons-Rimmer J; Ammoun S; Müller J; Lasonder E; Sharma V; Ercolano E; Hilton D; Taiwo I; Barczyk M; Hanemann CO
Oncogene; 2016 Jun; 35(26):3443-53. PubMed ID: 26549023
[TBL] [Abstract][Full Text] [Related]
10. Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function.
Yang C; Asthagiri AR; Iyer RR; Lu J; Xu DS; Ksendzovsky A; Brady RO; Zhuang Z; Lonser RR
Proc Natl Acad Sci U S A; 2011 Mar; 108(12):4980-5. PubMed ID: 21383154
[TBL] [Abstract][Full Text] [Related]
11. LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2.
Petrilli A; Copik A; Posadas M; Chang LS; Welling DB; Giovannini M; Fernández-Valle C
Oncogene; 2014 Jul; 33(27):3571-82. PubMed ID: 23934191
[TBL] [Abstract][Full Text] [Related]
12. β1 integrin-dependent Rac/group I PAK signaling mediates YAP activation of Yes-associated protein 1 (YAP1) via NF2/merlin.
Sabra H; Brunner M; Mandati V; Wehrle-Haller B; Lallemand D; Ribba AS; Chevalier G; Guardiola P; Block MR; Bouvard D
J Biol Chem; 2017 Nov; 292(47):19179-19197. PubMed ID: 28972170
[TBL] [Abstract][Full Text] [Related]
13. Neurofibromatosis 2.
Baser ME; R Evans DG; Gutmann DH
Curr Opin Neurol; 2003 Feb; 16(1):27-33. PubMed ID: 12544854
[TBL] [Abstract][Full Text] [Related]
14. NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.
Garcia-Rendueles ME; Ricarte-Filho JC; Untch BR; Landa I; Knauf JA; Voza F; Smith VE; Ganly I; Taylor BS; Persaud Y; Oler G; Fang Y; Jhanwar SC; Viale A; Heguy A; Huberman KH; Giancotti F; Ghossein R; Fagin JA
Cancer Discov; 2015 Nov; 5(11):1178-93. PubMed ID: 26359368
[TBL] [Abstract][Full Text] [Related]
15. NF2: the wizardry of merlin.
Xiao GH; Chernoff J; Testa JR
Genes Chromosomes Cancer; 2003 Dec; 38(4):389-99. PubMed ID: 14566860
[TBL] [Abstract][Full Text] [Related]
16. Functional analysis of the relationship between the neurofibromatosis 2 tumor suppressor and its binding partner, hepatocyte growth factor-regulated tyrosine kinase substrate.
Sun CX; Haipek C; Scoles DR; Pulst SM; Giovannini M; Komada M; Gutmann DH
Hum Mol Genet; 2002 Dec; 11(25):3167-78. PubMed ID: 12444101
[TBL] [Abstract][Full Text] [Related]
17. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression.
Xiao GH; Gallagher R; Shetler J; Skele K; Altomare DA; Pestell RG; Jhanwar S; Testa JR
Mol Cell Biol; 2005 Mar; 25(6):2384-94. PubMed ID: 15743831
[TBL] [Abstract][Full Text] [Related]
18. Merlin, a regulator of Hippo signaling, regulates Wnt/β-catenin signaling.
Kim S; Jho EH
BMB Rep; 2016 Jul; 49(7):357-8. PubMed ID: 27345717
[TBL] [Abstract][Full Text] [Related]
19. The genetic and molecular pathogenesis of NF1 and NF2.
Yohay KH
Semin Pediatr Neurol; 2006 Mar; 13(1):21-6. PubMed ID: 16818172
[TBL] [Abstract][Full Text] [Related]
20. Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.
Li W; Cooper J; Zhou L; Yang C; Erdjument-Bromage H; Zagzag D; Snuderl M; Ladanyi M; Hanemann CO; Zhou P; Karajannis MA; Giancotti FG
Cancer Cell; 2014 Jul; 26(1):48-60. PubMed ID: 25026211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]